Novel Virus Entry Portal Found

Researchers identify the target protein of a recently discovered human coronavirus, shedding light on infection and possible interspecies spread.

Written bySabrina Richards
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Coronaviruses displaying their characteristic halo of spike proteinsCDC/FRED MURPHY & SYLVIA WHITFIELDDutch researchers have identified the host cell protein that allows a recently discovered coronavirus to enter its target cells, according to a study published today (March 13) in Nature. The structure of the protein, called DPP4, appears to be conserved between bats and humans, suggesting that the new findings will help shed light on zoonotic transmission of the virus, as well as provide a target for potential vaccines.

“It’s a huge study,” said Ralph Baric, a virologist at the University of North Carolina, Chapel Hill, who was not involved in the research. “Any time you identify a receptor that a virus uses, it tells you a whole lot about its biology—where it targets, how it causes disease. And it tells you a lot about trans-species movement and the frequency of that event.” The fact that the new coronavirus can use both bat and human receptors for infection without drastically mutating raises the unsettling possibility that some coronaviruses are “pre-primed” to jump species, Baric added.

Until the deadly SARS virus was identified as a coronavirus in 2003, only two coronaviruses were known to infect humans, generally causing mild colds. Since then, three more have ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies